Background and objective: Talc pleurodesis is commonly performed to manage refractory pleural effusion or pneumothorax. It is considered as a safe procedure as long as a limited amount of large particle size talc is used. However, acute respiratory distress syndrome (ARDS) is a rare but serious complication after talc pleurodesis. We sought to determine the risk factors for the development of ARDS after pleurodesis using a limited amount of large particle size talc. Methods: We retrospectively reviewed patients who underwent pleurodesis with talc or OK-432 at the University of Tokyo Hospital. Results: Twenty-seven and 35 patients underwent chemical pleurodesis using large particle size talc (4 g or less) or OK-432, respectively. Four of 27 (15%) patients developed ARDS after talc pleurodesis. Patients who developed ARDS were significantly older than those who did not (median 80 vs 66 years, P = 0.02) and had a higher prevalence of underlying interstitial abnormalities on chest computed tomography (CT; 2/4 vs 1/23, P < 0.05). No patient developed ARDS after pleurodesis with OK-432. This is the first case series of ARDS after pleurodesis using a limited amount of large particle size talc. Conclusion: Older age and underlying interstitial abnormalities on chest CT seem to be risk factors for developing ARDS after talc pleurodesis.
INTRODUCTION
Pleural effusion or pneumothorax induces lung collapse and occasionally causes significant symptoms such as dyspnoea or cough, resulting in impairment of patients' quality of life. These patients usually require treatment. To treat pleural effusion, indwelling pleural catheters (IPC) are often used 1 ; however, they are expensive and are not approved in Japan. Pleurodesis is a procedure that obliterates the pleural cavity to prevent reaccumulation of fluid or air. 2, 3 There are two forms of pleurodesis: mechanical and chemical; mechanical pleurodesis includes abrasion or resection of pleura and/or the insertion of an IPC while chemical pleurodesis is produced by instilling sclerosing agents into the pleural cavity.
Many agents have been used for chemical pleurodesis. These include talc, [4] [5] [6] [7] minocycline, 3 bleomycin, 8 cisplatin 9 and OK-432. 10 Among them, talc is generally recognized as the most effective agent for chemical pleurodesis in malignant pleural effusion. 11 The efficacy of talc pleurodesis in refractory pneumothorax has also been shown. 12 Despite this demonstrated efficacy, several patients who developed acute respiratory distress syndrome (ARDS) after intrapleural talc administration were reported in the 1980s and 1990s, raising safety concerns. 13 Animals studies showed that smaller particles and higher doses of talc might increase the risk of acute respiratory failure. 14, 15 Subsequently, a prospective study showed that none of the 558 patients who underwent pleurodesis with 4 g of large particle size talc developed ARDS. 16 Only one patient with ARDS after pleurodesis using this product has been reported. 17 As it is a rare 
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Talc pleurodesis can cause acute respiratory distress syndrome (ARDS), but this rarely occurs with a limited amount of large particle size talc. We present four patients who developed ARDS after talc pleurodesis. Age and presence of interstitial abnormalities on chest computed tomography (CT) may be risk factors for ARDS after talc pleurodesis. complication, little is known about the risk factors associated with development of ARDS.
In Japan, the same sterile, large particle size talc was approved as Unitalc (Nobelpharma, Tokyo, Japan) in 2013. Herein, we present the first case series of ARDS after pleurodesis with limited amount of the large particle size talc and aim to determine the risk factors related to development of ARDS. Furthermore, we compare talc with OK-432, which was the agent of choice in Japan before talc was approved.
METHODS
At the University of Tokyo Hospital, all patients who underwent pleurodesis with sterile, large particle size talc (Unitalc; Nobelpharma) between August 2014 and January 2016 were identified by prescription records. Unitalc is derived from the same talc which is commonly used in European countries (Steritalc; Novatech, La Ciotat, France). Small particle size talc is removed and the mean particle size is calibrated to 25 μm. Patients who used OK-432 (Picibanil; Chugai Pharmaceutical, Tokyo, Japan) for pleurodesis between August 2013 and January 2016 were also reviewed. OK-432 is penicillin-treated, lyophilized Streptococcus pyogenes. The choice of talc or OK-432 was made at the treating physician's discretion. We obtained ethical approval from the University of Tokyo Hospital, and patients' confidentiality was maintained.
We collected the following data for all patients from their charts: age, sex, body mass index (BMI), Eastern Cooperative Oncology Group (ECOG) performance status, primary diagnosis, serum albumin level, smoking status (pack-year), presence of interstitial abnormalities on chest computed tomography (CT) and use of nonsteroidal anti-inflammatory drugs (NSAID). We also assessed the efficacy of the procedure and survival rate after 30 days. We considered pleurodesis to be a success unless another thoracentesis was required or chest X-ray showed accumulation of pleural fluid in more than one-third of the hemithorax. Diagnosis of ARDS was made based on the following criteria: onset within 7 days, development of bilateral opacities, respiratory failure which was not fully explained by cardiac failure or fluid overload, and peripheral oxygen saturation (SpO 2 ) < 90% while breathing ambient air. We used SpO 2 < 90% as a surrogate for partial pressure of oxygen/fraction of inspired oxygen (PaO 2 /FiO 2 ) < 300 because an arterial blood gas was not measured in many patients. None of the patients were intubated or used non-invasive positive pressure ventilation. All data were analysed with the use of JMP version 12.0 (SAS Institute, Cary, NC, USA). We compared two groups with Wilcoxon rank sum test for continuous variables, and Fisher's exact test for categorical variables. Continuous data are reported as median and range. Categorical data are reported as frequency and percentage. A P-value of < 0.05 was considered statistically significant.
RESULTS
We identified 29 instances of talc pleurodesis among 27 patients. Two patients underwent talc pleurodesis twice, and we only included their first procedures. All patients were administered 4 g of talc, except for one who received 3 g. Four patients (17%) developed ARDS after talc pleurodesis. The characteristics of patients with or without ARDS are shown in Table 1 . The most frequent cause of pleural effusion was lung adenocarcinoma. Patients who developed ARDS were significantly older than those who did not (median 80 vs 66 years, P = 0.02) and performance status tended to be worse among patients with ARDS than those without (P = 0.08). Underlying interstitial abnormalities on chest CT were seen more frequently among patients who developed ARDS (P < 0.05). The pleurodesis success rate was similar between the groups. Only one of the four patients with ARDS survived over 30 days; in contrast, all except for one patient without ARDS survived over 30 days. Table 2 shows individual data of the four patients who developed ARDS. All patients underwent pleurodesis with talc slurry, and developed ARDS within 4 days. Representative CT images are shown (Fig. 1) . After talc pleurodesis, CT revealed diffuse reticular pattern with ground-glass opacities in the ipsilateral lung, and patchy ground-glass opacity in the contralateral lung.
Thirty-five patients who underwent pleurodesis with OK-432 were identified, and none of them developed ARDS. Comparison between talc and OK-432 is summarized in Table 3 . There was no significant difference in baseline characteristics between both groups, including age, performance status and presence of interstitial abnormalities on chest CT. Success rate was similar between talc and OK-432 (81% vs 68%, P = 0.38).
DISCUSSION
This is the first case series of ARDS after pleurodesis using limited amount of large particle size talc. The results suggest that older age and presence of interstitial abnormalities on chest CT are potential risk factors. Pleurodesis with OK-432 may be a safer option for such patients.
We experienced four patients who developed ARDS after talc pleurodesis. Most reports of ARDS following talc pleurodesis are from North and South America, and reports from European countries are scarce, even when a limited amount of talc is used. For instance, ARDS developed in 8 of 89 patients (9%) in the study of Rehse et al., 18 and none of the 690 patients developed ARDS according to Cardillo et al., although 5 g of talc was used in both studies. 19 The difference in the incidence of ARDS may be caused by a difference in talc particle size. In North and South America, various types of talc preparation are used, whereas large particle size talc has been used in European countries. In fact, a previous prospective study using the large particle size talc within the recommended dose (i.e. < 5 g) confirmed efficacy and safety. 16 The form of talc (slurry or poudrage) may also lead to different consequences. However, only four patients underwent talc poudrage in our study, precluding a definitive conclusion. The present study is the first case series of ARDS after talc pleurodesis using limited amount of large particle size talc; our results indicate that even with 4 g of this talc, pleurodesis can still induce ARDS.
We also showed older age and presence of interstitial abnormalities on chest CT as risk factors for the development of ARDS after talc pleurodesis. Similar findings were seen in gefitinib-induced acute interstitial lung disease. 20 It appears safer to avoid talc pleurodesis in older patients and patients with underlying interstitial lung disease. Patients who developed ARDS also had worse performance status and lower albumin levels without reaching statistical significance, which may have been due to the small number of patients. Therefore, patients who are frailer may also have a higher risk for developing ARDS.
Before talc was approved, OK-432 had been the agent of choice for chemical pleurodesis in Japan. Its efficacy has already been demonstrated in previous studies. 21, 22 In the present study, no patient who received OK-432 developed ARDS. Although there were no significant differences in patients' characteristics between the OK-432 group and the talc group, no patient in the OK-432 had underlying interstitial lung abnormalities. On the other hand, there were no age differences between the groups. Therefore, OK-432 may be safer than talc in older patients at least in patients without underlying interstitial lung disease, although more patients are needed to confirm our finding.
The mechanism of ARDS after talc pleurodesis is not well understood. There is a hypothesis that pulmonary dissemination of talc particles and invasion into the systemic circulation induces inflammatory reactions. This hypothesis is supported by the finding that talc particles were found in the bronchoalveolar lavage obtained from patients who developed ARDS following talc pleurodesis. 23, 24 Moreover, autopsy of one of these patients revealed accumulation of talc in almost all organs. 24 In animal models, intrapleural injection of small size talc induced greater deposition of talc in lungs, and higher levels of interleukin-8 (IL-8) and vascular endothelial growth factor in serum and pleural Figure 1 Representative computed tomography (CT) images of pre-and post-pleurodesis. Postpleurodesis CT was taken 1 day after pleurodesis. Interstitial abnormalities developed in both lungs after intrapleural injection of talc. fluid when compared with mixed size talc. 25 IL-8 has been reported to play an important role in acute lung injury. 26 These results suggest that intrapleurally injected talc may invade the systemic circulation through the lung parenchyma, stimulating the production of inflammatory cytokines such as IL-8 which finally leads to lung injury. How large particle size talc causes respiratory failure preferentially in older patients is beyond the scope of this manuscript.
A limitation of this study is the small number of patients who developed ARDS. However, development of ARDS after pleurodesis with limited amount of large particle size talc is a rare complication, and reporting only four patients does not diminish its importance. In addition, the incidence of ARDS in this population was much higher than those of previous studies. 7, 27, 28 The high prevalence of underlying interstitial lung abnormalities (4/27, 11%) may contribute to this high incidence. Three of the four patients with interstitial lung abnormalities indeed developed ARDS after talc pleurodesis. Older age may also contribute, as the median age of patients who developed ARDS was much higher than those of previous studies. We must be aware that in older patients and patients with interstitial lung disease, 4 g of large particle size talc can still cause ARDS.
In summary, we present the first case series of ARDS after pleurodesis using limited amount of large particle size talc. Older age and underlying interstitial abnormalities on chest CT seem to be risk factors for development of ARDS after talc pleurodesis.
